S&CO Inc’s Alnylam Pharmaceuticals ALNY Stock Holding History

S&CO Inc’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.82M	Hold	7,400	–	–	0.1%	117
2026 Q2	$2.23M	Hold	7,400	–	–	0.13%	112
2026 Q1	$2.45M	Sell	7,400 -800	-10%	-$272K	0.15%	105
2025 Q4	$3.26M	Hold	8,200	–	–	0.2%	91
2025 Q3	$3.74M	Sell	8,200 -1,850	-18%	-$753K	0.23%	87
2025 Q2	$3.28M	Hold	10,050	–	–	0.21%	90
2025 Q1	$2.71M	Buy	10,050 +4,300	+75%	+$1.11M	0.18%	100
2024 Q4	$1.35M	Hold	5,750	–	–	0.09%	124
2024 Q3	$1.58M	Hold	5,750	–	–	0.1%	125
2024 Q2	$1.4M	Hold	5,750	–	–	0.1%	127
2024 Q1	$859K	Buy	+5,750	New	+$959K	0.06%	142

Other funds holding ALNY

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

S&CO Inc's ALNY Position: Q3 2026 in Review

S&CO Inc held its Alnylam Pharmaceuticals (ALNY) position steady in Q3 2026 at 7,400 shares worth $1.82M. The position accounts for 0.1% of the portfolio, ranked #117.

S&CO Inc first reported a position in ALNY in Q1 2024 and has held it in 11 quarters since. The position peaked at $3.74M in Q3 2025. 591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

S&CO Inc held 7,400 shares of Alnylam Pharmaceuticals worth $1.82M as of Q3 2026.
S&CO Inc left its Alnylam Pharmaceuticals share count unchanged in Q3 2026.
Alnylam Pharmaceuticals made up 0.1% of S&CO Inc's portfolio in Q3 2026, its #117 holding.
S&CO Inc first reported a position in Alnylam Pharmaceuticals in Q1 2024 and has held it in 11 quarters since.
S&CO Inc's Alnylam Pharmaceuticals position peaked at $3.74M in Q3 2025.
591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on S&CO Inc's 13F filing for Q3 2026, filed 10 Nov 2026.